ArticleAdvances in therapy2026
Experience with Tirzepatide and Weight Management During and After a Clinical Trial in Japanese Patients with Obesity Disease: A Qualitative Study.
Article in Advances in therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe phase 3 SURMOUNT-J clinical trial showed that Japanese adults with obesity disease achieved clinically meaningful body weight loss with once-weekly tirzepatide for 72 weeks. The primary objective of the present study was to explore participants' experiences with tirzepatide during SURMOUNT-J and body weight changes after the trial. Secondary objectives were to explore participant experiences with other weight loss treatments and body weight management after the trial, and to understand the healthcare provider support needs related to obesity disease treatment.
methodsThis was a cross-sectional, non-interventional, semi-structured, qualitative exit interview study conducted in Japan. Tirzepatide-treated participants in SURMOUNT-J who completed the 72-week study were recruited for this study. Participants completed a web-based interview about their experience during and after SURMOUNT-J.
resultsTwenty-nine participants completed the interviews. During SURMOUNT-J, 75.9% of participants experienced appetite loss, 72.4% experienced conscious eating habit changes, 62.1% had positive feelings associated with body weight loss, and 75.9% expressed willingness to continue drug therapy. Additionally, 58.6% experienced joy being able to choose new clothes, and 51.7% experienced lighter body movements. After SURMOUNT-J ended, 51.7% of participants maintained their changes in eating behavior, 44.8% were not able to maintain their changes in exercise/physical activity, and 65.5% experienced poor appetite control. The interviews revealed a potential unmet need to provide information to people with obesity disease and to connect them with appropriate medical interventions.
conclusionsStudy participants who received tirzepatide treatment reported that they were able to maintain their changes in eating behaviors but not exercise habits after SURMOUNT-J. Three-quarters of participants expressed a desire to continue drug therapy for obesity disease treatment.
Indexed as
Identifiers
42334799What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.